Ambu A S Ord (AMBFF) Q3 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Ambu Earnings Release Q3 twenty twenty five-twenty six Conference Call. I'm Vicki, the Chorus Call operator. I would like to remind you that all participants will be in listen only mode and the conference is being recorded. The presentation will be followed by a Q and A session. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Britt Malbu A Jensen, CEO. Please go ahead. Thank you, and good morning, everyone, and welcome to this earnings call for our Q3 'twenty five, 'twenty six results. My name is Britt Malbou Jensen. I'm the CEO and of Ambu, and I have Henrik Skagbender, our CFO, with me today. So if we move to the next slide and then the next one again, I'll start with a review of our business and progress before I hand over to Henrik to go through our financials. And starting on the next slide, please, with the highlights for Q3. Overall, we see a very strong shift towards single use endoscopy. We continue to lead this conversion to single use by bringing new innovative solutions to the market that can address a wide range of procedures, also supported by key opinion leaders across the different areas that we are in. In the quarter, this was most evident in the reacceleration we have seen in respiratory, which, as you know, is the first area we entered. Here we grew 17.1, which was driven by our bronchoscopy portfolio but supported by the strong synergistic effect from our new radiolaryngoscope solution, SureSide. For urology, E and C and GI, we grew 15% in the quarter, resulting in a 16% growth overall of endoscopy solutions. In AMPM, after two quarters of negative growth, we returned to positive growth with 1.6%, and we also announced recently a new solution, Neu...